Innovatie en intellectueel eigendom · 22-5-19961 min lezen
Notice of Two Year Exclusivity Period; DAYPRORegister Oxaprozin
Lokale automatische vertaling · Oorspronkelijke brontaal
Samenvatting
The Patent and Trademark Office has received notification from G. D. Searle & Co. that it claims entitlement under section 2105 of the FDA Export Reform and Enhancement Act of 1996 (Chapter 1A of Pub. L. No. 104-134) for its drug product DAYPRO oxaprozin.